Nektar Therapeutics announces press release on start of Phase 3 ZENITH AD program for rezpegaldesleukin in atopic dermatitis
NKTR•Development timeline
Initial Phase 3 topline data are expected in mid-2028, and a BLA submission is targeted for 2029.
Phase 3 program begins
Nektar Therapeutics published a press release announcing the start of its Phase 3 ZENITH AD program for rezpegaldesleukin in moderate-to-severe atopic dermatitis.
Two 510-patient registrational trials have begun; an additional 510-patient study in previously treated patients is slated to start in September.
